VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales

Key Takeaways VKTX posted a Q2 loss of $0.58 per share, missing estimates and widening from $0.20 last year.Higher R&D costs from clinical trials and staffing drove a 153% year-over-year expense increase.Viking launched its phase III VANQUISH obesity trials and eyes a new IND filing by year-end.Viking Therapeutics (VKTX) reported second-quarter 2025 loss of 58 cents per share, wider than the Zacks Consensus Estimate of a loss of 44 cents. The company had incurred a loss of 20 cents per share in the year-ago ...